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Abstract
The naturally hypercoagulable state occurring during pregnancy and anatomical 
changes and changes in the plasma volume are the main reasons for the increased risk 
of venous thromboembolism (VTE) during pregnancy and puerperium. This risk is par‐
ticularly enhanced in the presence of thrombophilia and a previous history of VTE. The 
cornerstone for treating and preventing VTE is low molecular weight heparin (LMWH). 
There is currently no consensus on the dosing and the need for monitoring treatment 
with LMWH, and varying protocols are used in different clinics. The risk models used to 
stratify the risk for recurrence are based on the presence of factors such as previous VTE, 
familial history and thrombophilia and lead to decisions on the dosing and the duration 
of thromboprophylaxis. Treatment with LMWH is considered safe and effective, with 
low incidence of adverse effects (bleeding, osteoporosis, etc.) and recurrence of VTE. The 
use of direct oral anticoagulants is currently not recommended in this setting, but case 
series have not indicated increased embryopathy. The lack of international guidelines 
and large studies underlines the need for collaboration in order to further improve out‐
comes and patient safety.
Keywords: pregnancy, postpartum, thromboembolism, anticoagulation, 
thromboprophylaxis
1. Introduction: venous thromboembolism
Venous thromboembolism (VTE) is a relatively common disease with an incidence of 104–183 
per 100,000 person‐years among persons of European ancestry [1]. The clinical manifestations 
of VTE are pulmonary embolism (PE) and deep vein thrombosis (DVT), which is most often 
located in the lower extremities [2]. The incidence for PE and DVT ranges from 29 to 78 and 45 
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to 117 per 100,000 person‐years, respectively [3, 4]. VTE is associated with significant mortal‐
ity and morbidity. Sudden death is the initial manifestation for about 25% of patients with PE 
[5], and PE is an independent marker for reduced survival early after its debut [6, 7]. Around 
20–50% of patients with DVT will develop post‐thrombotic syndrome [8] with the symptoms 
varying from mild pain and swelling to severe venous insufficiency and ulcerations [9, 10]. 
About 5% of the patients with PE can develop chronic thromboembolic pulmonary hyperten‐
sion, leading to reduced lung capacity and heart failure [11].
The pathophysiology of VTE is complicated and will not be reviewed here. The basic mecha‐
nism behind the pathogenesis of VTE is likely attributed to the so‐called Virchow's triad: (i) 
changes in blood flow (i.e. stasis), (ii) vascular endothelial injury and (iii) changes in blood 
components (i.e. inherited or acquired hypercoagulable states, thrombophilia) [12].
Venous thromboembolism is a multifactorial disease. The risk for VTE increases in the 
presence of acquired and inherited risk factors, such as thrombophilia [13], immobiliza‐
tion, trauma, recent surgery, cancer, etc. [14, 15]. Additionally, the female sex hormones, 
predominantly oestrogen, affect the coagulation cascade, tipping it towards hypercoagu‐
lability and therefore increasing the risk for thrombosis [16]. For example, the use of com‐
bined oral contraceptives [17] and hormone replacement therapy [18] are well‐established 
risk factors for venous thrombosis, especially if other risk factors are present. Pregnancy 
is a naturally hypercoagulable state, and the risk for thrombosis is increased throughout 
pregnancy and persisting through puerperium [19, 20]. VTE is the seventh leading cause of 
maternal morbidity and mortality in Western countries [21, 22], accounting for ca. 10% of 
all maternal deaths [23]. Considering the burden of the disease and its impact on maternal 
and foetal health, it is imperative to early recognize and effectively treat venous thrombosis 
during pregnancy and postpartum. In this chapter, we describe the mechanisms behind 
the increased thrombotic risk during that period, as well as the principles of treatment and 
prevention of VTE.
2. Risk factors for venous thromboembolism
2.1. Pregnancy as a hypercoagulable state
During pregnancy, the coagulation balance leans towards hypercoagulability, as a means to 
protect the woman from fatal bleeding in the case of a miscarriage and during labour. This is 
mediated mainly by an increase in most procoagulant factors and a decrease in some antico‐
agulant factors, as well as a decrease in fibrinolytic activity [24].
The levels of fibrinogen begin to increase during the first trimester, reaching profoundly high 
levels during late pregnancy [25]. Along with fibrinogen, coagulation factors II, VII, VIII, X, XII 
and XIII increase by 20–200% during pregnancy [26]. Factors V and IX are slightly increased 
during normal pregnancy or unchanged according to some studies [25, 26]. Factor XIII 
increases at the beginning of pregnancy and decreases gradually afterwards, reaching levels 
about 50% of the normal non‐pregnant value at term [25]. Factor XI is the only coagulation 
factor that decreases during pregnancy, with average values at about 60–70% of its normal 
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value (non‐pregnant) [25, 27]. Von Willebrand factor increases during pregnancy. During the 
first half of the pregnancy, it follows the increase in factor VIII, but thereafter increases dis‐
proportionally, increasing the ratio of von Willebrand factor antigen to factor VIII coagulant 
activity from one to about two [25, 28]. Tissue factor does not change during pregnancy [29]. 
The anticoagulant protein S decreases during pregnancy; this decrease is particularly evident 
when measuring free protein S and less evident when measuring total protein S. The decrease 
in protein S persists up to at least 8 weeks postpartum [30]. Protein C remains unchanged [31], 
but pregnancy induces acquired activated protein C (APC) resistance [32]. Antithrombin val‐
ues have previously been regarded as virtually unchanged, but later studies have shown that 
they fall to a level of about 20% of baseline levels [33]. Following partus, antithrombin levels 
fall additionally to 30% below baseline, with the lowest levels noted 12 hours postpartum, and 
return to normal about 3 days after birth [34, 35]. Tissue factor pathway inhibitor and throm‐
bomodulin increase during pregnancy [36, 37].
Pregnancy is characterized by hypofibrinolysis. Fibrinolytic inhibitors such as thrombin activat‐
able fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 (PAI‐1), and PAI‐2, which 
is practically non‐existent outside of pregnancy, increase [38]. In particular, PAI‐1 levels increase 
significantly due to production from endothelial cells of the placenta and decidua [27, 30].
Plasminogen and tissue‐type plasminogen activator increase [39]. The urokinase‐type plas‐
minogen activator is also increased during normal pregnancy [40]. Thrombin cleavage 
products such as D‐dimer and fibrin monomers increase, suggesting ongoing and active 
coagulation [41, 42].
Platelet counts remain within the range of normal values in most pregnancies but can be 
lower in about 5% of pregnancies (gestational thrombocytopenia) [43, 44], whereas the mean 
platelet volume is unchanged [45] or increased [46]. Gestational thrombocytopenia is usu‐
ally mild and occurs during the third trimester. It resolves spontaneously following deliv‐
ery and platelet counts continue to increase for the first 3–4 weeks postpartum as a marker 
for increased inflammatory activity. Thereafter, platelet counts return to normal values [47]. 
Although increased platelet aggregation has been reported during pregnancy [48], the issue 
of increased platelet activation in an uncomplicated pregnancy is still controversial [49, 50].
Following delivery, there is increased inflammatory activity; C‐reactive protein, fibrinogen, 
antithrombin and platelet counts increase during the first week postpartum [27]. Blood coag‐
ulation returns to normal in the first 6–8 weeks postpartum [30, 35].
2.2. Other risk factors for thromboembolism
Along with the haemostatic changes mentioned in Section 1.1, increased venous capacitance 
and compression of large veins, such as inferior vena cava and iliac vein, by the growing 
uterus cause stasis [51] and additionally increase the thrombotic risk.
In addition to pregnancy‐specific factors, the thrombotic risk increases in the presence of 
other elements such as thrombophilia. Both acquired (antiphospholipid syndrome) and 
inherited (such as factor V Leiden, prothrombin gene mutation G20210A, protein S defi‐
ciency, protein C deficiency, antithrombin deficiency) thrombophilic conditions are among 
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the factors taken into consideration when calculating the individual thrombotic risk [52–54]. 
The grade to which these factors contribute varies depending on the specific thrombophilia. 
There is also evidence that women with thrombophilia have a greater risk of pregnancy com‐
plications such as placental abruption, pre‐eclampsia, foetal growth restriction, stillbirth and 
possibly recurrent miscarriage [55].
Other factors that increase the risk for thrombosis, in both pregnant and non‐pregnant popula‐
tion, are a medical history of previous VTE, positive familial history for VTE, immobilization, 
obesity, etc. [56]. Some of those factors are very important when stratifying the individual risk 
for VTE during pregnancy and deciding on appropriate treatment strategy.
3. Venous thromboembolism in pregnancy and postpartum
3.1. Incidence and type of venous thromboembolism
The risk for VTE during pregnancy is increased, with rates varying from 4 to 50 times higher 
than in the non‐pregnant population. However, despite the increased risk for VTE during 
pregnancy, the incidence is rather low. In the United States, venous thrombosis occurs in 
about 1 in 500–2000 pregnancies [57, 58], with DVT being 3–4 times more usual than PE 
[19, 59]. In Europe the incidence is about 0.71 per 72,000 deliveries, with two‐thirds occur‐
ring prenatally and the remaining one‐third postnatally [60]. The risk for VTE is most pro‐
nounced during the postpartum period. Most studies show that the antenatal risk for DVT 
is equally distributed among the three trimesters [57, 58, 61], whereas PE occurs more often 
(up to 60%) 4–6 weeks postpartum [62]. During pregnancy, the thrombotic risk is addition‐
ally enhanced by the presence of factors such as multiple births, inflammation, infection and 
diabetes [63, 64]. On the other hand, during the postpartum period, the risk increases in the 
presence of factors such as caesarean section, obstetric bleeding, pre‐eclampsia/eclampsia 
and infection [20, 64], indicating that the risk factors for thrombosis during puerperium are 
different compared to the risk factors during pregnancy.
Pelvic vein thrombosis is a rare event outside of pelvic surgery and pregnancy. However, its 
incidence increases from accounting for less than 1% for all DVT events to 10% of all DVT cases 
during pregnancy [65]. Additionally, pregnancy‐associated pelvic thrombosis is believed to 
be isolated and not originating from a distal part of the leg [66]. The majority (ca. 90%) of DVT 
during pregnancy is located in the left leg, probably as a result of the compression of the left 
iliac artery by the right iliac artery and the inferior vena cava by the growing uterus [58, 67].
3.2. Anticoagulant treatment
Despite the differences in dose recommendations among different committees, the preferred 
drug for treating VTE during pregnancy is unanimously low molecular weight heparin 
(LMWH), replacing the previous recommendation on the use of unfractionated heparin 
(UFH) [68, 69]. LMWH has been shown to cause less bleeding episodes and has a lower 
risk of causing heparin‐induced thrombocytopenia (HIT) and osteoporosis compared to 
UFH [70, 71]. In contrast to vitamin K antagonists that cross the placenta and can cause 
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teratogenicity, LMWH does not cross the placenta, is easy to administer and has a consis‐
tent bioavailability [72]. Fondaparinux does not cross the placenta either, but its use during 
pregnancy has not been studied extensively; it is primarily recommended for patients with 
allergy to heparin or HIT [62].
Considering the significant morbidity and mortality associated with VTE during pregnancy 
and postpartum, prompt diagnosis and treatment of thrombosis is essential to ensure a good 
maternal and foetal outcome. Although there have not been any major studies on the safety of 
treating pregnant patients with DVT as outpatients, data from the treatment of non‐pregnant 
patients suggest that this is safe as long as the patient's condition allows it [62]. On the other 
hand, the safety of treating patients with PE at home, especially on the first days following 
the event, is more uncertain.
There is no international consensus on the optimal dose for treatment of VTE during preg‐
nancy. LMWH is predominantly eliminated renally, and in the non‐pregnant population 
with a glomerular filtration rate (GFR) of more than 30 mL/min, e.g. no severe renal function 
impairment, there is no need to adjust the dose or monitor the treatment. However, in preg‐
nant women, due to increased plasma volume and subsequent heparin clearance, as well as 
weight increase [73], the need for both dose adjustment and monitoring can arise, though 
expert opinions dissent on that. The initial dose depends on the maternal weight according 
to the guidelines for non‐pregnant patients [69]. The following dosages are recommended 
for the most commonly used LMWH: dalteparin 200 units/kg once daily or 100 units/kg 
every 12 hours, tinzaparin 175 units/kg once daily, enoxaparin 1 mg/kg every 12 hours and 
nadroparin 86 units/kg every 12 hours or 171 units/kg once daily [69]. In Sweden, the recom‐
mended start dose of LMWH (dalteparin) is 125 units/kg twice daily or 250 units/kg once 
daily, since pregnant women need more (25–30%) of LMWH compared to non‐pregnant 
women [74]. The twice‐daily protocol is usually preferred in Sweden since clinical observa‐
tions have indicated a lower bleeding risk.
There is no consensus on whether LMWH should be given once or twice daily, either. Some 
physicians choose the twice‐daily regimen in order to better accommodate the changes in the 
plasma volume and renal clearance of LMWH during late pregnancy. However, it has been 
shown [75, 76] that the risk of recurrence does not increase with once‐daily anticoagulant 
regimens in pregnant patients. This, combined with the simplicity of the once‐daily treatment 
and the need for good compliance, makes it an attractive alternative for many physicians and 
patients.
There are different approaches for the rest of the treatment, following the initial dose, mainly 
on whether the dosage should be adjusted. In some centres, the dose remains unchanged 
throughout pregnancy [77]. If an adjustment is deemed necessary, it can be performed either 
according to the patient's increasing weight [77, 78] or by periodically measuring anti‐Xa 
LMWH levels [69, 73]. The target level is most commonly set to 0.6–1.0 units/mL for a bid 
regimen and higher for a once‐daily regimen, measured 4–6 hours following administration 
[62]. There are, however, data suggesting that those adjustments are not necessary in most 
women receiving therapeutic dose of anticoagulants [79–81] showing neither an increase in 
safety and efficacy of treatment nor a decrease in bleeding complications. The tests currently 
utilized for the measurement of anti‐Xa LMWH are costly and have been reported to be not 
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always reliable [69]. As such, there is no general recommendation on the use of such tests for 
dose adjustments, but such tests can be useful in patients with renal impairment and extreme 
low or high body weight [69].
A review by Gandara E et al. [82] on studies where women who were treated with full‐dose 
anticoagulation for up to 6 weeks following diagnosis of VTE (predominantly DVT) and then 
changed to a dose somewhat lower than 75% of full dose but higher than prophylactic dose, 
showed that the risk for recurrence was low (ca. 0.65%). In the American College of Chest 
Physicians (ACCP) Evidence‐Based Clinical Practice Guidelines from 2012, dose reduction is 
named as an alternative approach, especially in patients with high risk of complications, such 
as osteoporosis and bleeding [62].
Unfractionated heparin can be used as alternative to LMWH in some cases, for example, in 
patients with severe renal impairment as well as when thrombolysis is considered or when 
urgent surgery or delivery is planned. When UFH is given, the recommended regimen is 
twice daily, with doses adjusted to prolong activated partial thromboplastin time (aPTT) into 
therapeutic range as measured 6 hours following administration [69]. Caution is advised 
since it is known that aPTT measurement during pregnancy is not as reliable as in non‐preg‐
nant patients. The increased levels of factor VIII and of heparin‐binding protein observed dur‐
ing pregnancy lead to corresponding decreases in aPPT and increased UFH requirement. It 
is unclear whether the attenuation in dosage leads to significant bleeding complications [77].
Data on thrombolysis during pregnancy, including data on maternal and foetal safety, is very 
limited. As such, thrombolytic treatment should be discussed only in the setting of life‐threat‐
ening PE or in cases of severe DVT where there is a risk of losing a limb [62, 69].
Choosing a delivery option for women on anticoagulation should optimally have been dis‐
cussed in advance by a multidisciplinary team of coagulation experts, obstetricians and 
anaesthesiologists. The decision should be based on factors such as the patient's risk profile 
for both bleeding and thrombosis, the time elapsed since diagnosis of VTE and the actual 
dosage of anticoagulants, as well as the patient's own preferences. Planned labour induction 
can be successful in preventing anticoagulation‐associated bleedings during partus. In order 
to ensure patient safety, it is recommended to discontinue anticoagulant treatment 24 hours 
prior to delivery or neuraxial anaesthesia [62].
The optimal duration of anticoagulation is under discussion. Considering the fact that the 
increased risk for thrombosis persists throughout pregnancy and puerperium, the current 
recommendation is that anticoagulation continues for the duration of pregnancy for at least 
6 weeks postpartum for a minimum time period of 3 months [62, 69].
3.3. Efficacy and safety of anticoagulant treatment: therapeutic dose
The major adverse effect of treatment with anticoagulants is bleeding. According to the ACCP 
guidelines from 2012 [62], major nonfatal maternal haemorrhage is defined as a symptomatic 
bleeding complication into a critical site (intracranial, intraspinal, retroperitoneal, pericardial, etc.), 
under pregnancy or within 6 weeks postpartum that results in a fall in haemoglobin level of 20 g/L 
and to transfusion of two or more units of whole blood or red cells [83].
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According to a study from 1989, the risk for major antepartum bleeding in pregnant women 
under anticoagulation with UFH is about 1%, e.g. comparable to the rates noted for non‐preg‐
nant patients [72]. LMWH, the drug of choice for treatment and prevention of VTE during 
pregnancy, has an even milder bleeding complication profile compared to UFH [71, 84]. A 
review by Greer IA et al. [85] reported bleeding rates of 0.43% (for antepartum haemorrhage) 
and 0.94% for postpartum haemorrhage (PPH). PPH is defined as blood loss exceeding 500 
ml (vaginal delivery) or 1000 ml (caesarean delivery) and is divided into primary PPH, occur‐
ring within the first 24 hours after partus, and secondary, occurring between 24 hours up to 
12 weeks after partus [86]. Primary PPH has been reported to occur in 1.9% of women receiv‐
ing treatment dose of anticoagulants [84]. In a study by the authors (unpublished data) on 39 
patients with antenatal pelvic vein thrombosis treated with full (adjusted)‐dose LMWH, the 
risk for PPH (<1000 ml) was somewhat increased; however, the risk for severe PPH (>1000 ml) 
was not increased compared to women without anticoagulation therapy [87], and the rates 
were comparable to other studies [86]. In the majority of those patients, LMWH was discon‐
tinued 24 hours prior to delivery. Knol et al. [86] did not observe an increase in the number of 
transfused red blood cell units in a population receiving full‐dose anticoagulation, suggesting 
that the majority of observed PPH lacked major clinical significance and the treatment should 
be deemed safe.
The risk for both HIT and osteoporosis is lower with LMWH compared to UFH [88, 89]. 
Long‐term treatment with UFH has been reported to cause osteoporotic fractures in 2–3% of 
patients [90], with the rate increasing to 15% in older populations for UFH but being lower for 
LMWH (3%) [91]. The risk for HIT in patients with UFH has been reported to vary from 0.8% 
[92] to 2.7% [70] with the respective rates for patients with LMWH being 0% (70). However, 
antibodies developed in patients with HIT under treatment with UFH have a high risk of 
cross‐reacting with LMWH if such treatment is given [93].
No recurrent thrombosis was recorded for the remainder of their pregnancies in women with 
pelvic vein thrombosis in the study by the authors mentioned earlier (unpublished data). 
Similarly, in other studies, the recurrence rates for patients receiving anticoagulant treatment 
were low [75], indicating a high efficacy of treatment.
4. Thromboprophylaxis in pregnancy and postpartum
The cornerstone of the pharmacological treatment for prevention of recurrent or first‐time VTE 
is LMWH [69]. The grade of the recurrence risk depends on the risk factors for thrombosis, such 
as previous VTE, thrombophilia and family history, and the patients are treated accordingly.
4.1. Risk stratification for recurrent venous thromboembolism during pregnancy and 
postpartum
A history of previous thrombosis is the strongest risk factor to predict recurrence risk [94]. 
Among studies of different designs, the risk for recurrent VTE in women not receiving throm‐
boprophylaxis ranges from 2.4% [95] to 6% [96]. Despite the relatively low recurrence rate, 
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the potentially catastrophic implications of an antenatal or postpartum VTE for mother and 
foetus have to be considered.
In order to evaluate the risk for thrombotic recurrence and decide on the type of recom‐
mended prophylaxis, the patients can be divided into four groups of increasing risk accord‐
ing to the following suggestion: (a) low risk (previous VTE provoked by a transient risk 
factor), (b) intermediate risk (spontaneous VTE or VTE associated with hormonal treatment 
or pregnancy), (c) high risk (multiple previous VTE or permanent risk factors for thrombosis) 
and (d) very high risk (patients with previous VTE and indication for continuing treatment 
with anticoagulants) [62, 69]. Postpartum (6 weeks following delivery) thromboprophylaxis 
with LMWH or vitamin K antagonists should be considered for all groups, and the need for 
additional antenatal prophylaxis should be carefully assessed for groups b–d [62, 69]. These 
recommendations are subject to change, and the patient can be recommended ante‐ and/or 
postpartum prophylaxis depending on the concomitant presence of additional risk factors 
[68, 69, 97]. If antenatal prophylaxis is given, it should be introduced early upon confirmation 
of pregnancy [69].
4.1.1. Risk stratification for first‐time venous thromboembolism during pregnancy according to 
family history and thrombophilia
The risk for VTE in individuals with thrombophilia varies, with the highest risk observed on 
patients with homozygosity for factor V Leiden and prothrombin gene G20210A mutation, 
whereas the corresponding heterozygotes had considerably lower risks [98]. Familial history 
of VTE further increases the risk for a first‐time thrombosis during pregnancy by two‐ to 
fourfold [99].
Similarly to Section 3.1.1, women with thrombophilia and heredity for VTE without previous 
VTE are divided into different risk groups: (a) women with family history who are homo‐
zygous for factor V Leiden or prothrombin gene G20210A mutation, (b) women with family 
history and all other thrombophilias, (c) women without family history who are homozy‐
gous for factor V Leiden or prothrombin gene G20210A mutation and (d) women with all 
thrombophilias except for those mentioned in (a) without family history. Antenatal and post‐
partum prophylaxis is recommended for group a, whereas groups b and c are thought to 
benefit from 6 weeks postpartum thromboprophylaxis. No drug treatment is required for 
women in group d, unless in the presence of other risk factors, most significantly caesarean 
section [62, 69]. A special mention should be made to antithrombin deficiency, which is the 
only other thrombophilia, except for those mentioned in (a) that could warranty antepartum 
prophylaxis [69].
4.1.2. Risk stratification for first‐time venous thromboembolism during pregnancy according to 
clinical factors
Factors such as BMI > 25 (prior to pregnancy), immobility, caesarean section and co‐morbidi‐
ties (e.g. systemic lupus erythematosus, sickle cell disease) increase the risk for thrombosis 
independently of the presence of thrombophilia and family history [64, 100]. The extent to 
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which the thrombotic risk is increased by those factors individually is unclear, but is generally 
considered as modest [62]. However, when antepartum immobility is combined with co‐mor‐
bidities, the clinician should consider administering thromboprophylaxis during pregnancy 
and shortly postpartum (7 days) [69].
4.2. Type of thromboprophylaxis
The optimal dose of LMWH thromboprophylaxis is unclear, since studies that compare the 
different dosages are lacking. For patients with previous VTE who have intermediate or high 
risk for recurrent thrombosis during pregnancy (see 3.1), it is recommended to use prophylac‐
tic or intermediate‐dose LMWH. Examples of prophylactic dose LMWH are dalteparin 5000 
units subcutaneously every 24 hours, tinzaparin 4500 units subcutaneously every 24 hours, 
nadroparin 2850 units subcutaneously every 24 hours or enoxaparin 40 mg subcutaneously 
every 24 hours [62, 96, 101]. Examples of intermediate‐dose LMWH include dalteparin 5000 
units subcutaneously every 12 hours or enoxaparin 40 mg subcutaneously every 12 hours 
[62]. The aforementioned dosages can be adjusted depending on body weight and/or renal 
function [62].
The recommended dose for patients at very high risk for recurrent VTE is higher (adjusted 
dose or 75% of therapeutic dose) [69]. Adjusted LMWH dose is the dose required in order to 
maintain a peak level of anti‐factor Xa LMWH of 0.2–0.6 units/mL [102] or a trough level of 
0.1–0.2 U/ml [103]. For women without a history of VTE who require thromboprophylaxis, 
it is recommended to administer prophylactic or intermediate‐dose LMWH [62]. However, 
the decision on the optimal dosage is individual, and factors such as risk for complications 
(bleeding) and patient preferences should be weighed in.
4.3. Efficacy and safety of anticoagulant treatment: prophylactic dose
The risk of bleeding with prophylactic dose of LMWH is generally low and the treatment is 
considered safe. Most studies in the field do not make a distinction between high‐ and nor‐
mal‐dose thromboprophylaxis, which makes the results difficult to interpret and the bleeding 
rates cannot be surely attributed to one type of treatment. In a recent study the bleeding rates 
were very low according to data derived from 10 studies where the patients were given nor‐
mal‐dose thromboprophylaxis, with overall antepartum rates for severe bleeding (ISTH defi‐
nition [83]) reported as low as 0% and postpartum rates as 0.3% [104]. In a study by Lepercq 
et al. that was not included in the meta‐analysis in [94], a bleeding incidence of 11.5% was 
reported; however, in this study, patients with both high and normal prophylaxis doses were 
included [105]. In a study by the authors, the incidence of bleeding during pregnancy was 
12% (n = 6) and postpartum haemorrhage had an overall incidence of 20% (n = 10) in a cohort 
of 49 patients treated with high‐dose thromboprophylaxis at the Department of Obstetrics 
and Gynaecology at Karolinska University Hospital in Solna for a time period from 2004 to 
2014 (unpublished data). In the same cohort, the incidence of VTE was 2% (n = 1, unpublished 
data). In a study by Pettilä et al. where the patients were treated with normal‐dose thrombo‐
prophylaxis (UFH or dalteparin), the VTE incidence was 0% [106].
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The mean bone density of patients treated with prophylactic doses of LMWH (dalteparin) 
did not differ from that of patients treated with placebo whereas for patients treated with 
UFH it was significantly decreased [107]. Similarly, in another study, no difference in bone 
density was observed between patients receiving prophylactic doses of LMWH and placebo 
[88]. There are, however, some case reports confirming LMWH‐associated osteoporosis [62], 
and the risk for each patient should be evaluated individually.
5. Future perspectives
5.1. Direct oral anticoagulants
Pregnant and lactating women were excluded from the clinical trials on direct oral anticoagulants 
(DOAC), e.g. dabigatran, rivaroxaban, apixaban and edoxaban, as there is data suggesting that 
they may cross the placenta with unclear effects [108]. A recent article [109] identified 233 cases 
where pregnant women had been exposed to DOAC, with the majority having been exposed 
to rivaroxaban. The authors did not report an increased risk for embryotoxicity; however, the 
number of patients was small and the reports were incomplete and diverse [109]. There are cur‐
rently no guidelines recommending the use of DOAC during pregnancy and breast‐feeding.
5.2. Studies
Despite the effectiveness and safety of anticoagulant treatment during pregnancy and postpar‐
tum, issues such as the optimal way to adjust and monitor the therapeutic dose of LMWH but 
also the ideal dose and duration of thromboprophylaxis are yet to be conclusively addressed. 
Additionally, although there are guidelines from different work groups, differences in local 
practice remain. There is a need for studies on larger cohorts under international collabora‐
tions in order to further advance treatment efficacy and ensure patient safety.
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